1 / 38

TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE AND BIOEQUIVALENCE WITH A FOCUS ON ARTEMISININ

TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE AND BIOEQUIVALENCE WITH A FOCUS ON ARTEMISININS. Why are bioavailability / bioequivalence studies necessary? An Introduction to Bioequivalence Studies Presented by: Hans Kemmler, Consultant to WHO

rasha
Download Presentation

TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE AND BIOEQUIVALENCE WITH A FOCUS ON ARTEMISININ

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. TRAINING WORKSHOP ON PHARMACEUTICAL QUALITY, GOOD MANUFACTURING PRACTICE AND BIOEQUIVALENCE WITH A FOCUS ON ARTEMISININS Why are bioavailability / bioequivalence studies necessary? An Introduction to Bioequivalence Studies Presented by: Hans Kemmler, Consultant to WHO White Sands, 23.Aug. 2006 TANZANIA 21 - 25 AUGUST 2006

  2. Background:First Product to Market • Innovator’s Product • Quality • Safety and efficacy • Based on extensive clinical trials • Expensive • Time consuming TANZANIA 21 - 25 AUGUST 2006

  3. Background:Other products with same medicinal ingredient • Subsequent-entry products • Generic products • Multisource products • How do these products gain marketing authorization? TANZANIA 21 - 25 AUGUST 2006

  4. Pharmaceutical equivalence • Same amount of the same active pharmaceutical ingredient • Salts, esters • Same dosage form • Comparable dosage forms • e.g., tablet vs. capsule • Same route of administration • Is pharmaceutical equivalence enough? TANZANIA 21 - 25 AUGUST 2006

  5. Sometimes pharmaceutical equivalence is enough • Aqueous solutions • Intravenous solutions • Intramuscular, subcutaneous • Oral solutions • Otic or ophthalmic solutions • Topical preparations • Solutions for nasal administration • Powders for reconstitution as solution • Gases TANZANIA 21 - 25 AUGUST 2006

  6. Sometimes it is not enough • Pharmaceutical equivalence by itself does not necessarily imply therapeutic equivalence • Therapeutic equivalence: • Pharmaceutically equivalent • Same safety and efficacy profiles after administration of same dose TANZANIA 21 - 25 AUGUST 2006

  7. Pharmaceutical Equivalents Test Reference Possible Differences • Drug particle size • Excipients • Manufacturing Equipment or Process • Site of manufacture Could lead to differences in product performance in vivo TANZANIA 21 - 25 AUGUST 2006

  8. Additional data is required • Oral immediate release products with systemic action • Generally required for solid oral dosage forms • Critical use • Narrow therapeutic range • Bioavailability problems associated with the active ingredient • Problematic polymorphism, excipient interaction, or sensitivity to manufacturing processes TANZANIA 21 - 25 AUGUST 2006

  9. Additional data is required • Oral modified release products with systemic action • Fixed dose combination products with systemic action • When at least one component requires study • Non-oral / non-parental products with systemic action • Non-solution products with non-systemic action TANZANIA 21 - 25 AUGUST 2006

  10. Marketing authorization of multisource products • Extensive clinical trials to demonstrate safety and efficacy • Interchangeability? • Demonstration of equivalence to reference (comparator) product • Interchangeability • Therapeutic equivalence TANZANIA 21 - 25 AUGUST 2006

  11. Marketing authorization through equivalence • Suitable methods for assessing equivalence: • Comparative pharmacokinetic studies • Comparative pharmacodynamic studies • Comparative clinical trials • Comparative in vitro tests TANZANIA 21 - 25 AUGUST 2006

  12. Comparative Pharmacokinetic Studies • In vivo measurement of active ingredient • “Some” relationship between concentration and safety/efficacy • Product performance is the key • Comparative bioavailability TANZANIA 21 - 25 AUGUST 2006

  13. Bioavailability • The rate and extent to which a substance or its active moiety is delivered from a pharmaceutical form and becomes available in the general circulation.” Reference: intravenous administration = 100% bioavailability TANZANIA 21 - 25 AUGUST 2006

  14. Important Pharmacokinetic Parameters • AUC: area under the concentration-time curve  measure of the extent of bioavailability • Cmax: the observed maximum concentration of drug  measure of both the rate of absorption and the extent of bioavailability • tmax: the time after administration of drug at which Cmax is observed  measure of the rate of absorption TANZANIA 21 - 25 AUGUST 2006

  15. Plasma concentration time profile concentration Cmax AUC time Tmax TANZANIA 21 - 25 AUGUST 2006

  16. Bioequivalence Two products are bioequivalent if • they are pharmaceutically equivalent • bioavailabilities (both rate and extent) after administration in the same molar dose are similar to such a degree that their effects can be expected to be essentially the same TANZANIA 21 - 25 AUGUST 2006

  17. Bioavailability • Absolute bioavailability (F): • Relative bioavailability (Frel) TANZANIA 21 - 25 AUGUST 2006

  18. Bioavailability: Same Dose • Absolute bioavailability (F): • Relative bioavailability (Frel) TANZANIA 21 - 25 AUGUST 2006

  19. Therapeutic Equivalence • Therapeutic equivalence: • Pharmaceutically equivalent • Same safety and efficacy profiles after administration of same dose: bioequivalent • Interchangeability TANZANIA 21 - 25 AUGUST 2006

  20. Comparative Pharmacodynamic Studies • Not recommended when: • active ingredient is absorbed into the systemic circulation • pharmacokinetic study can be conducted • Local action / no systemic absorption TANZANIA 21 - 25 AUGUST 2006

  21. Comparative Clinical Studies • Pharmacokinetic profile not possible • Lack of suitable pharmacodynamic endpoint • Typically insensitive TANZANIA 21 - 25 AUGUST 2006

  22. Comparative in vitro Studies • May be suitable in lieu of in vivo studies under certain circumstances • Requirements for waiver to be discussed TANZANIA 21 - 25 AUGUST 2006

  23. When are bioequivalence studies employed? • Multisource product vs. Innovative product • Pre-approval changes • Bridging studies • Post-approval changes • Additional strengths of existing product TANZANIA 21 - 25 AUGUST 2006

  24. Bioequivalence Studies:Basic Design Considerations • Minimize variability not attributable to formulations • Minimize bias • REMEMBER: goal is to compare performance of the two products TANZANIA 21 - 25 AUGUST 2006

  25. “Gold Standard” Study Design • Single-dose, two-period, crossover • Healthy volunteers • Subjects receive each formulation once • Adequate washout TANZANIA 21 - 25 AUGUST 2006

  26. Multiple-dose Studies • More relevant clinically? • Less sensitive to formulation differences TANZANIA 21 - 25 AUGUST 2006

  27. Multiple-dose Studies may be employed when: • Drug is too potent/toxic for administration in healthy volunteers • Patients / no interruption of therapy • Extended/modified release products • Accumulation using recommended dosing interval • In addition to single-dose studies TANZANIA 21 - 25 AUGUST 2006

  28. Multiple-dose Studies may be employed when: • Non-linear pharmacokinetics at steady-state (e.g., saturable metabolism) • Assay not sufficiently sensitive for single-dose study TANZANIA 21 - 25 AUGUST 2006

  29. Crossover vs. Parallel Designs • Crossover design preferred • Intra-subject comparison • Lower variability • Generally fewer subjects required • Parallel design may be useful • Drug with very long half-life • Crossover design not practical TANZANIA 21 - 25 AUGUST 2006

  30. Parallel Design Considerations • Ensure adequate number of subjects • Adequate sample collection • Completion of Gastrointestinal transit / absorption process • 72 hours normally sufficient TANZANIA 21 - 25 AUGUST 2006

  31. Fasted vs. Fed Designs • Fasted study design preferred • Minimize variability not attributable to formulation • Better able to detect formulation differences TANZANIA 21 - 25 AUGUST 2006

  32. Fed Study Designs may be employed when: • Significant gastrointestinal (GI) disturbance caused by fasted administration • Product labeling restricts administration to fed state TANZANIA 21 - 25 AUGUST 2006

  33. Fed Study Design Considerations • Fed conditions depend on local diet and customs • Dependent on reason for fed design • Avoiding GI disturbance • Minimal meal to minimize impact • Required due to drug substance / dosage form • Modified-release products TANZANIA 21 - 25 AUGUST 2006

  34. Fed Study Design Considerations cont. • Required due to drug substance / dosage form • Complicated pharmacokinetics • Known effect of food on drug substance • Fed conditions designed to promote maximal perturbation • High fat • High Calorie • Warm TANZANIA 21 - 25 AUGUST 2006

  35. Replicate vs. non-replicate designs • Standard approach • Non-replicated • Single administration of each product • Average bioequivalence TANZANIA 21 - 25 AUGUST 2006

  36. Replicate Designs • Typically four-period design • Each product administered twice • Intra-subject variability • Subject X formulation interaction • Different approaches possible • Average bioequivalence • Individual bioequivalence TANZANIA 21 - 25 AUGUST 2006

  37. Replicate Designs • Advantages • More information available • Different approaches to assessment possible • Disadvantages • Bigger commitment for volunteers • More administrations to healthy volunteers • More expensive to conduct TANZANIA 21 - 25 AUGUST 2006

  38. Discussion • Questions • Comments • Opinions TANZANIA 21 - 25 AUGUST 2006

More Related